Crowded rheumatoid arthritis category gets JAK reality check, while TNF stalwarts continue to dominate: study

The FDA’s black box label slap on JAK rheumatoid arthritis brands last year hit where it hurt – in class reputation and prescriptions. But Pfizer …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Crowd­ed rheuma­toid arthri­tis cat­e­go­ry gets JAK re­al­i­ty check, while TNF stal­warts con­tin­ue to dom­i­nate: study